Statins in Patients with Chronic Kidney Disease: Evidence from Systematic Reviews and Randomized Clinical Trials by Navaneethan, Sankar D et al.
PLoS Medicine  |  www.plosmedicine.org 0615
Best Practice
May 2006  |  Volume 3  |  Issue 5  |  e123
S
tatins are recommended 
for primary and secondary 
prevention of cardiovascular 
disease in the general population 
with elevated low-density lipoprotein 
(LDL) cholesterol based on extensive 
randomized trial evidence of 
cardiovascular beneﬁ  ts. Statin use in 
patients with kidney disease, including 
patients on dialysis, is also increasing, 
although fewer and smaller trials exist. 
Is the use of statins in patients with 
chronic kidney disease supported by 
the available randomized clinical trial 
evidence? In this article, the question 
was addressed by reviewing current 
published trials or systematic reviews 
on this topic. Available data conﬁ  rm 
the cardiovascular beneﬁ  ts of statins in 
patients with chronic kidney disease, 
although their impact on all-cause 
mortality is still not established. Statins 
are safe in these high-risk patients.
Statins in Patients with Kidney 
Disease: Evidence from Systematic 
Reviews and Randomized Clinical 
Trials
Case scenario. A 72-year-old, diabetic 
white male on dialysis for six months 
presents for a routine ofﬁ  ce visit. 
He has a total cholesterol level of 
190 mg/dl, LDL cholesterol level of 
136 mg/dl, high-density lipoprotein 
(HDL) cholesterol level of 37 mg/dl, 
and triglycerides level of 192 mg/
dl. Given his dialysis status, clinical 
history of diabetes, and presence of 
hyperlipidemia, this is a patient at 
high risk for cardiovascular events. 
He is very concerned about the high 
cholesterol levels, and you discuss 
the option of starting treatment 
with a lipid-lowering agent (statins). 
However, before making that decision, 
you reschedule him for another visit 
within one week and propose that you 
will have a look at the most updated 
literature—particularly meta-analysis 
and randomized clinical trials data, 
with a major focus on patients on 
dialysis—having recently heard that 
a new trial conducted in diabetic 
patients on dialysis found no signiﬁ  cant 
improvements in cardiac end points 
with statins. You are also aware of the 
signiﬁ  cant toxicity associated with 
statins and, hence, would like to make 
the best “evidence-based” decision for 
your patient, based on a beneﬁ  t–harm 
trade-off. 
Background. Cardiovascular diseases 
account for approximately 50% of 
deaths in patients with end-stage 
renal disease [1]. Patients on dialysis 
with concomitant cardiovascular 
disease have higher all-cause mortality 
rates compared with the general 
population. The prevalence of 
traditional cardiovascular risk factors 
such as diabetes and hypertension 
is also higher in patients on dialysis 
compared with the general population. 
Dyslipidemia is common in this group, 
with mildly elevated LDL cholesterol 
levels and a marked predominance of 
highly atherogenic, small, dense LDL 
particles [2]. Paradoxically, but not 
surprisingly given their biased nature 
when assessing intervention issues, 
some observational studies have found 
a signiﬁ  cant increase while others 
showed a signiﬁ  cant decrease in the 
risk of death in individuals with lower 
cholesterol levels and chronic kidney 
disease [3–6]. Additionally, currently 
available randomized clinical trials 
in chronic kidney diseases are few 
and small, and often provide data 
on surrogate end points alone, with 
limited information on mortality and 
cardiovascular event rates.
Despite conﬂ  icting results and a 
scant evidence base, statins have been 
recommended broadly in patients 
on dialysis by various guidelines, 
on the grounds of beneﬁ  cial effects 
found in observational data or in 
trials conducted both in populations 
on dialysis and in other populations 
(those not on dialysis). The National 
Kidney Foundation–Kidney Disease 
Outcomes Quality Initiative guidelines 
recommend the use of statins in 
chronic kidney disease stages 3, 4, and 
5 (stage 3 glomerular ﬁ  ltration rate 
[GFR], 30–59 ml/min; stage 4 GFR, 
15–29 ml/min; stage 5 GFR, less than 
15 ml/min) with LDL levels greater 
than 130 mg/dl [7]. Globally, more 
than 1.3 million people receive dialysis, 
and more than 600,000 patients receive 
dialysis in the United States and 
Europe alone [8]. Statin use in patients 
on dialysis varies according to the 
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geographic region, with at least 40%–
50% of US patients on dialysis receiving 
statin therapy [7]. Given the paucity of 
evidence in this ﬁ  eld, there appears to 
be conﬂ  ict between recommendations 
from guidelines, evidence, and current 
practice patterns. Furthermore, given 
the signiﬁ  cantly larger number of 
patients taking statins and being cared 
for by internists, it is imperative to 
review the evidence supporting its use.
Systematic Reviews of Statins 
in Patients with Chronic Kidney 
Disease
You performed a literature search in 
the Renal Health Library (http:⁄⁄www.
cochrane-renal.org/renalhealthlibrary.
php), which is produced by the 
Cochrane Renal Group, and includes 
the most updated list of randomized 
clinical trials (n is approximately 
8,000) and systematic reviews (n is 
approximately 50) conducted in 
populations with renal diseases. Your 
search identiﬁ  ed a systematic review of 
statins in patients on dialysis [9]. This 
review included six randomized clinical 
trials, which were of short duration 
(Table 1). Statins reduced total 
cholesterol (ﬁ  ve studies, 357 patients; 
weighted mean difference, −53.74 mg/
dl [1.40 mmol/L]; 95% conﬁ  dence 
interval [CI], −66.95–−40.54) and LDL 
cholesterol levels (ﬁ  ve studies, 357 
patients; weighted mean difference, 
−55.40 mg/dl [1.44 mmol/L]; 95% CI, 
−69.90–−40.90) similar to the general 
population, without any increase in the 
rate of adverse events (hepatotoxicity 
abnormal liver function test results 
or rhabdomyolysis-elevated creatine 
kinase levels). However, data on 
cardiovascular and cerebrovascular 
events in patients on dialysis were never 
looked at by the trials and, hence, 
not analyzed in this review. Since 
publication of that Cochrane review, 
which is currently being updated, a 
large statin trial in patients on dialysis 
(4D trial) came into the public 
domain. This trial found no signiﬁ  cant 
difference in the rates of cardiovascular 
mortality and events in diabetic patients 
on dialysis receiving statins compared 
with those who did not receive statins. 
In the Renal Health Library, there 
was no systematic review of randomized 
trials analyzing the role of statins in 
patients with earlier stages of chronic 
kidney disease (“predialysis” patients), 
and there was one non-Cochrane 
review that analyzed the role of statins 
in patients with kidney transplants 
[10]. This latter review concluded 
that in transplant recipients, statins 
may reduce clinical cardiac events, 
along with improvement in surrogate 
end points (lipid markers). In 
summary, these data mainly indicate 
that statins are effective in improving 
surrogate end points, but have never 
been strongly demonstrated to 
affect mortality and cardiovascular 
events. You therefore go further in 
your analysis of trials published after 
the systematic reviews, and, hence, 
not included in those analyses. In 
particular, you focus on individual 
clinical trials conducted in patients on 
dialysis, predialysis patients, or patients 
with renal transplants.
Recent Clinical Trial Evidence 
for Use of Statins in Patients on 
Dialysis 
Recently, the largest clinical trial 
of statins in patients on dialysis was 
published [11]. The 4D trial analyzed 
the efﬁ  cacy of atorvastatin in 1,200 
patients with diabetes on hemodialysis 
in Germany. The primary end point 
was a composite of death from 
cardiac causes, fatal stroke, nonfatal 
myocardial infarction, or nonfatal 
stroke—whichever occurred ﬁ  rst. Even 
though the impact on cholesterol 
reduction was similar to that observed 
in the general population, atorvastatin 
had no statistically signiﬁ  cant effect 
on the composite end point (relative 
risk [RR], 0.92; 95% CI, 0.77–1.10; p = 
0.37). The use of atorvastatin decreased 
the number of cardiovascular events 
(fatal and nonfatal) signiﬁ  cantly (RR, 
0.82; 95% CI, 0.68–0.99; p = 0.03), but 
the impact on all-cause mortality was 
not signiﬁ  cant in comparison with 
placebo (RR, 0.93; 95% CI, 0.79–1.08; 
p = 0.33). 
The United Kingdom heart and 
renal protection (HARP) trial analyzed 
the safety and efﬁ  cacy of simvastatin in 
three subsets of patients with chronic 
kidney disease, including predialysis, 
renal transplant, and also patients 
treated with dialysis [12]. It concluded 
that the use of simvastatin consistently 
decreased cholesterol levels in 
all subgroups, without additional 
toxicity (i.e., simvastatin therapy was 
not associated with excess risk for 
hepatotoxicity or rhabdomyolysis). 
Again, despite the relatively large 
sample size (n = 448; patients on 
dialysis = 73), long-term outcomes, 
particularly mortality rates, were not 
reported in this trial.
Recent Clinical Trial Evidence 
for Use of Statins in Predialysis 
Patients and Recipients of Renal 
Transplants
Tonelli et al. analyzed the role of 
pravastatin in 1,711 patients with 
creatinine clearance less than 75 
ml/min and not on dialysis [13]. 
This study was a subanalysis of the 
larger cholesterol and recurrent 
events (CARE) trial that enrolled 
4,159 patients with prior myocardial 
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Table 1. Characteristics of the Populations and Interventions in the Short-Term Randomized Controlled Trials of Statins Conducted in 
Patients on Dialysis Focusing on Surrogate End Points
Study Dialysis  Modality  a Intervention Study Duration (Months) Number of Patients
Statin Control
Diepeveen et al. [17] CAPD, HD Atorvastatin, 10 mg 3 13 24
Harris et al. [18] CAPD Atorvastatin, 10–40 mg 4 59 71
Lins et al.[19] HD Atorvastatin, 10 mg 3 23 19
Walker et al. [20] CAPD, HD Simvastatin, 5–20 mg 6 54 53
Saltissi et al. [21] CAPD, HD Simvastatin, 20 mg 6 37 18
Baigent et al. [12] CAPD, HD Simvastatin, 20 mg 12 35 38
aAll these studies measured only cholesterol levels and adverse events (liver function tests and creatine kinase levels).
CAPD, continuous ambulatory peritoneal dialysis; HD, hemodialysis.
DOI: 10.1371/journal.pmed.0030123.t001PLoS Medicine  |  www.plosmedicine.org 0617
infarction and cholesterol levels 
greater than 240 mg/dl; it has been 
subsequently included in meta-
analyses including the large Pravastatin 
Pooling Project and has been widely 
disseminated [14]. The study of 
Tonelli et al. concluded that the use 
of pravastatin decreased the incidence 
of major coronary events, with no 
impact on all-cause mortality (Table 
2). The study individually may not 
be adequately powered to detect the 
impact on all-cause mortality rates in 
predialysis patients with kidney disease, 
but the subsequent Pravastatin Pooling 
Project analyses, including additional 
information in predialysis patients 
from the West of Scotland coronary 
prevention study (WOSCOPS) and 
long-term intervention with pravastatin 
in ischemic disease (LIPID) studies, 
demonstrates a signiﬁ  cant reduction 
in the risk of all-cause mortality with 
statins in these patients (RR, 0.81; 95% 
CI, 0.73–0.89; p = 0.03). 
In the assessment of lescol in renal 
transplantation (ALERT) trial, the use 
of ﬂ  uvastatin in patients with renal 
transplants has been found to decrease 
coronary events and cardiovascular 
mortality rates by an extent similar 
to that observed in patients without 
kidney disease, although there was no 
impact found on all-cause mortality 
[15]. In terms of cardiovascular end 
points, both the studies demonstrated 
that the beneﬁ  ts of statins in predialysis 
populations and in recipients of 
renal transplants are similar to those 
observed in the general population 
(patients without kidney disease) 
(Table 2).
Implications for Clinical Practice
Coming back to the original focus on 
our patient on dialysis, what does the 
current trial and systematic review 
evidence tells us about statins and 
cardiovascular disease in this scenario? 
The systematic reviews looked at 
surrogate end points alone. If these are 
validated surrogates, as in the general 
population, then statins reduce the 
levels of the surrogate and also the 
rate of the major event distal to the 
surrogate in the causal pathway of 
events. In summary, provided total 
cholesterol and LDL cholesterol levels 
are validated surrogate end points, 
statins reduce their levels, and this 
implies cardiovascular morbidity and 
mortality. The fact that the 4D trial 
found an effect on the surrogate but 
not on all-cause or cardiovascular 
mortality may indicate that initiation 
of statin therapy in patients on dialysis 
may be too late, and statin use should 
be considered in patients with chronic 
kidney disease before they reach 
dialysis. In fact, both predialysis patients 
and recipients of renal transplants 
signiﬁ  cantly beneﬁ  t from statins for 
both cardiovascular morbidity and 
mortality and all-cause mortality. 
In both patients in the predialysis 
stage and those with transplants, 
cardiovascular event and cardiac 
mortality rates decreased similarly to 
the general population (about 20%). 
This decrease was not found in patients 
on dialysis with diabetes, where much 
more severe comorbidities occur such 
that the beneﬁ  ts of statins are less likely 
to occur, in particular with respect to 
survival. 
Hence, it is reasonable that despite 
absence of trial evidence in the dialysis 
population, statins should confer 
some beneﬁ  t, and perhaps dose, 
duration, cointerventions, and other 
still unexplored aspects may play a role 
in determining whether they result 
in a survival advantage. Very likely, a 
meta-analysis including predialysis, 
dialysis, and transplant data will show 
a cumulative estimate of signiﬁ  cant 
reduction for both cardiovascular and 
total mortality, and will demonstrate 
that the stage of chronic kidney disease 
(predialysis, dialysis, and transplant) 
is not an effect modiﬁ  er. Such 
meta-analyses are being conducted. 
Furthermore, other randomized trials 
may address the question. These are 
also ongoing. In particular, there are 
two randomized trials currently in 
progress: the study of heart and renal 
protection (SHARP) trial, which will 
include 3,000 patients on dialysis and 
6,000 predialysis patients, and the 
AURORA study, which will include 
2,700 patients on hemodialysis [16]. 
Their results are awaited to build on 
current knowledge and to make a 
ﬁ  nal informed decision on whether a 
statin is beneﬁ  cial in dialysis, but there 
is insufﬁ  cient evidence at present to 
say that statins should not be used, 
particularly in light of no substantial 
evidence of harm. 
What Will You Suggest to Your 
Patient?
Your patient comes for the scheduled 
follow-up visit. You tell him about the 
studies that looked at whether use of 
statins in his condition is supported 
by evidence from randomized trials. 
Statins have in fact been proven to 
decrease the cardiovascular event rates 
in patients with chronic kidney disease, 
and no substantial evidence of harm 
was demonstrated in these patients. 
In comparison with trials conducted 
in all other populations, there are no 
major counterarguments that statins 
should be harmful to him, although 
the only trial conducted in individuals 
with diabetes on dialysis did not 
conﬁ  rm any cardiovascular or survival 
beneﬁ  t—perhaps for methodological 
reasons, mainly including sample 
size/low power—selecting a high-risk 
population where major beneﬁ  ts were 
not likely to be seen, even though 
harm was not observed. Despite your 
strictly “evidence-based” approach to 
decision making, you decide with your 
patient that you will follow the current 
recommendations for statin use by the 
National Kidney Foundation–Kidney 
Disease Outcomes Quality Initiative 
guidelines, and look forward to the 
Table 2. Results of the Three Major Statin Trials Reporting Patient-Level End Points in Patients with Chronic Kidney Disease
Stage of Kidney 
Disease
Number of Patients/
Study Duration 
(Years)
Cardiovascular Eventsa 
(Relative Risk, [95% 
conﬁ  dence interval], p value)
Cardiovascular Mortality 
(Relative Risk, [95% 
conﬁ  dence interval], p value)
All-Cause Mortality (Relative 
Risk, [95% conﬁ  dence 
interval], p value)
Predialysis [13] 1,711/5  0.72, (0.59–0.88), 0.001 0.72, (0.55–0.95), 0.02 0.81, (0.61–1.08), 0.14
Hemodialysis [11] 1,255/3.9  0.82, (0.68–0.99), 0.03 0.81, (0.64–1.03), 0.08 0.93, (0.79–1.08), 0.33
Transplantation [15] 2,102/5  0.65, (0.48–0.88), 0.005 0.62, (0.40–0.96), 0.03 1.02, (0.81–1.30), 0.40
aIncludes nonfatal myocardial infarction and the need for revascularization procedures.
DOI: 10.1371/journal.pmed.0030123.t002
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results of currently ongoing trials. 
In fact, you discuss with your patient 
that you will seek information about 
whether he himself may be enrolled in 
one of the ongoing trials of statins.  
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